It was Monday March 21 when SwedenBIO, for the 6th consecutive year, stood host for its Life Science Investment Day Scandinavia. The most interesting part of the meeting was undoubtedly all the investors gathered in one place.  Notable was also a clear spoken strategy among investors: many prefered to co-invest in order to minimize the refinancing risk and to secure a steadier cash flow.

I wonder when we will see similar tendencies among Biotech companies: co-researching with their competition.  In fact PWC recently presented a report identifying what they believe life science companies can do to better cope with the challenges of today’s life Science industry. Sharing knowledge could be one way forward when funding is scarce, an idea that also has the potential to decrease research costs and shorten development timelines.

For all of you not attending the Life Science investment day, below is a list of some of the investors. Martin Heidecker with Boehringer Ingelheim venture funds mentioned they review about 500 companies each year of which one or two receives funding. In other words, the competition is still fierce. Before you contact and pitch an Investor, listening to David S Rose talking to a TED audience on pitching to VCs might be beneficial.

God luck and contact A+ Science when you are about to enter the clinical phase.

Investors present at the Life Science Investment Day Scandinavia

Aravis
Simon Nebel
Funding early stage companies from seed to late stage preclinical, read more.

Boehringer Ingelheim venture Fund
Martin Heidecker
New treatments and modalities and technology platforms. Prefers early investment, read more here.

Forbion Capital Partners
Christina Takke
Late pre-clinical and onwards, 70% drug development 30% medtech. Find out more

DnB Nor
Øyvind W. Bekke
Bank, different value proposition, healthcare since 2007. Contact them here.

Gilde Healthcare partners
Dirk Kersten
Have made 20 investments over ten years. Also supports M&A and IPO:s. Meet them here.

GSK CEEDD
Declan Jones
From target to clinical proof of concept, biotechs that share their goals. What CEEDD look for.

Lundbeckfond Ventures
Johan Kördel
Targets European companies. Later stage drug discovery. Read more here.

Merch Serono Ventures
Roel Bulthius
€40 miljon to work with. Have made 5 investments over the last 2 years.  Find out more.

MVM Capital Partners
Alex Pasteur
London based, hands-on. Focuses on the risk and return characteristics. Find out more here.

Novartis Venture Funds
Markus Goebel
Novel therapeutics and platforms. Early stage investments to help build the company. More criteria’s.

Novo Seeds
Stefan Christgau
Early stage projects, often from the academia (no connection with Novo Nordisk). Read more here.

TVM Capital
Peter Neubeck
Compound ready for phase III, prefer being joined by a big pharma. Read more here.

Valedo Partners Fund 1 AB
Allan Engström
Established and profitable companies with clear strong market positions within their respective segments. More here.

SEB Venture Capital
Viktor Drvota
Invests up to 100 MSEK, invests mainly in Life Science and technology. Read more at their page.

Healthcap
Dr Björn Odlander
Entirely focused on the Life Science Industry. Read more.

SLS Invest
Hans Andreasson
With offices in Stockholm and Copenhagen, they have €160 M I assets. Read more.